Acceleration of the loss of the first-phase insulin response during the progression to type 1 diabetes in diabetes prevention trial-type 1 participants
- PMID: 23863814
- PMCID: PMC3837047
- DOI: 10.2337/db13-0656
Acceleration of the loss of the first-phase insulin response during the progression to type 1 diabetes in diabetes prevention trial-type 1 participants
Abstract
We studied the change in the first-phase insulin response (FPIR) during the progression to type 1 diabetes (T1D). Seventy-four oral insulin trial progressors to T1D from the Diabetes Prevention Trial-Type 1 with at least one FPIR measurement after baseline and before diagnosis were studied. The FPIR was examined longitudinally in 26 progressors who had FPIR measurements during each of the 3 years before diagnosis. The association between the change from the baseline FPIR to the last FPIR and time to diagnosis was studied in the remainder (n = 48). The 74 progressors had lower baseline FPIR values than nonprogressors (n = 270), with adjustments made for age and BMI. In the longitudinal analysis of the 26 progressors, there was a greater decline in the FPIR from 1.5 to 0.5 years before diagnosis than from 2.5 to 1.5 years before diagnosis. This accelerated decline was also evident in a regression analysis of the 48 remaining progressors in whom the rate of decline became more marked with the approaching diagnosis. The patterns of decline were similar between the longitudinal and regression analyses. There is an acceleration of decline in the FPIR during the progression to T1D, which becomes especially marked between 1.5 and 0.5 years before diagnosis.
Figures


Comment in
-
Following the fate of the failing β-cell: new insights from first-phase insulin responses.Diabetes. 2013 Dec;62(12):3990-2. doi: 10.2337/db13-1314. Diabetes. 2013. PMID: 24264397 Free PMC article. No abstract available.
References
-
- Vardi P, Crisa L, Jackson RA. Predictive value of intravenous glucose tolerance test insulin secretion less than or greater than the first percentile in islet cell antibody positive relatives of type 1 (insulin-dependent) diabetic patients. Diabetologia 1991;34:93–102 - PubMed
-
- Chase HP, Voss MA, Butler-Simon N, Hoops S, O’Brien D, Dobersen MJ. Diagnosis of pre-type I diabetes. J Pediatr 1987;111:807–812 - PubMed
-
- Srikanta S, Ganda OP, Rabizadeh A, Soeldner JS, Eisenbarth GS. First-degree relatives of patients with type I diabetes mellitus. Islet-cell antibodies and abnormal insulin secretion. N Engl J Med 1985;313:461–464 - PubMed
-
- Ginsberg-Fellner F, Witt ME, Franklin BH, et al. Triad of markers for identifying children at high risk of developing insulin-dependent diabetes mellitus. JAMA 1985;254:1469–1472 - PubMed
-
- Skyler JS, Krischer JP, Wolfsdorf J, et al. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1. Diabetes Care 2005;28:1068–1076 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- UL1 RR024139/RR/NCRR NIH HHS/United States
- U01-DK-084565/DK/NIDDK NIH HHS/United States
- P30-DK-017047/DK/NIDDK NIH HHS/United States
- U01 DK085463/DK/NIDDK NIH HHS/United States
- UL1-RR-024139/RR/NCRR NIH HHS/United States
- UL1-RR-024153/RR/NCRR NIH HHS/United States
- U01-DK-061042/DK/NIDDK NIH HHS/United States
- UL1 RR024982/RR/NCRR NIH HHS/United States
- UL1 RR025744/RR/NCRR NIH HHS/United States
- U01 DK061042/DK/NIDDK NIH HHS/United States
- U01 DK061041/DK/NIDDK NIH HHS/United States
- UL1-RR-024975/RR/NCRR NIH HHS/United States
- M01 RR000400/RR/NCRR NIH HHS/United States
- U01 DK061010/DK/NIDDK NIH HHS/United States
- UL1 RR025761/RR/NCRR NIH HHS/United States
- U01 DK061040/DK/NIDDK NIH HHS/United States
- UL1 RR024153/RR/NCRR NIH HHS/United States
- UL1 RR029890/RR/NCRR NIH HHS/United States
- UL1 TR001105/TR/NCATS NIH HHS/United States
- UL1 RR031986/RR/NCRR NIH HHS/United States
- U01 DK085466/DK/NIDDK NIH HHS/United States
- U01-DK-085509/DK/NIDDK NIH HHS/United States
- U01 DK061058/DK/NIDDK NIH HHS/United States
- U01 DK085505/DK/NIDDK NIH HHS/United States
- U01 DK085453/DK/NIDDK NIH HHS/United States
- UL1 RR025780/RR/NCRR NIH HHS/United States
- U01-DK-061036/DK/NIDDK NIH HHS/United States
- U01-DK-061041/DK/NIDDK NIH HHS/United States
- U01-DK-085463/DK/NIDDK NIH HHS/United States
- U01-DK-085466/DK/NIDDK NIH HHS/United States
- UL1-RR-031986/RR/NCRR NIH HHS/United States
- UL1 RR024131/RR/NCRR NIH HHS/United States
- U01 DK085499/DK/NIDDK NIH HHS/United States
- U01-DK-085505/DK/NIDDK NIH HHS/United States
- U01 DK061055/DK/NIDDK NIH HHS/United States
- U01 DK061036/DK/NIDDK NIH HHS/United States
- P30 DK045735/DK/NIDDK NIH HHS/United States
- U01-DK-061055/DK/NIDDK NIH HHS/United States
- UL1 TR001085/TR/NCATS NIH HHS/United States
- UL1-RR-025744/RR/NCRR NIH HHS/United States
- U01 DK061034/DK/NIDDK NIH HHS/United States
- UL1-RR-025780/RR/NCRR NIH HHS/United States
- UL1-RR-024982/RR/NCRR NIH HHS/United States
- UL1 TR001082/TR/NCATS NIH HHS/United States
- U01 DK085461/DK/NIDDK NIH HHS/United States
- U01-DK-061058/DK/NIDDK NIH HHS/United States
- U01 DK085509/DK/NIDDK NIH HHS/United States
- UL1 RR024975/RR/NCRR NIH HHS/United States
- UL1-RR-025761/RR/NCRR NIH HHS/United States
- UL1-RR-029890/RR/NCRR NIH HHS/United States
- UC4 DK117009/DK/NIDDK NIH HHS/United States
- U01-DK-085461/DK/NIDDK NIH HHS/United States
- U01-DK-061034/DK/NIDDK NIH HHS/United States
- U01-DK-061040/DK/NIDDK NIH HHS/United States
- UL1-RR-024131/RR/NCRR NIH HHS/United States
- U01-DK-061010/DK/NIDDK NIH HHS/United States
- UC4 DK097835/DK/NIDDK NIH HHS/United States
- M01-RR-00400/RR/NCRR NIH HHS/United States
- HHSN267200800019C/LM/NLM NIH HHS/United States
- U01-DK-085453/DK/NIDDK NIH HHS/United States
- U01-DK-061016/DK/NIDDK NIH HHS/United States
- U01-DK-085499/DK/NIDDK NIH HHS/United States
- P30 DK017047/DK/NIDDK NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical